CoChat

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

Open access

The DOI matches its Crossref record; 26 of the 29 references it cites were found in a registry or an index.

Abstract

Context: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is characterized by impaired cortisol synthesis and excess androgen production. Corticotropin-releasing factor type 1 receptor (CRF1R) antagonism may decrease adrenal androgen production. Objective: This work aimed to evaluate the safety, tolerability, and efficacy of crinecerfont (NBI-74788), a selective CRF1R antagonist, in 21OHD. Methods: This open-label, phase 2 study, with sequential cohort design (NCT03525886), took place in 6 centers in the United States. Participants included men and women, aged 18 to 50 years, with 21OHD. Interventions included 4 crinecerfont regimens, each administered orally for 14 consecutive days: 50 or 100 mg once daily at bedtime (cohorts 1 and 2, respectively); 100 mg once daily in the evening (cohort 3); and 100 mg twice daily (cohort 4). Participants could enroll in more than 1 cohort. Main outcomes included changes from baseline to day 14 in adrenocorticotropin (ACTH), 17-hydroxyprogesterone (17OHP), androstenedione, and testosterone. Results: Eighteen participants (11 women, 7 men) were enrolled: cohort 1 (n = 8), cohort 2 (n = 7), cohort 3 (n = 8), cohort 4 (n = 8). Mean age was 31 years; 94% were White. Median percent reductions were more than 60% for ACTH (–66%), 17OHP (–64%), and androstenedione (–64%) with crinecerfont 100 mg twice a day. In female participants, 73% (8/11) had a 50% or greater reduction in testosterone levels; male participants had median 26% to 65% decreases in androstenedione/testosterone ratios. Conclusion: Crinecerfont treatment for 14 days lowered ACTH and afforded clinically meaningful reductions of elevated 17OHP, androstenedione, testosterone (women), or androstenedione/testosterone ratio (men) in adults with 21OHD. Longer-term studies are required to evaluate the effects of crinecerfont on clinical end points of disordered steroidogenesis and glucocorticoid exposure in patients with 21OHD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgab749

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study design. Blue triangles denote sample collection. In all cohorts, sampling for the 24-hour baseline period (day –7 to –6) matched the sampling schedule during crinecerfont treatment. For the baseline and day 1 visits, participants received their prescribed glucocorticoid dose after sample collection at 10:00 (end of the morning window); for the day 14 visit, glucocorticoid was administered after sample collection at 14:00. GC, glucocorticoid.
Figure 1. Study design. Blue triangles denote sample collection. In all cohorts, sampling for the 24-hour baseline period (day –7 to –6) matched the sampling schedule during crinecerfont treatment. For the baseline and day 1 visits, participants received their prescribed glucocorticoid dose after sample collection at 10:00 (end of the morning window); for the day 14 visit, glucocorticoid was administered after sample collection at 14:00. GC, glucocorticoid.CC BY-NC-ND · PubMed Central
Figure 2. Twenty-four–hour profiles. For cohorts 1 and 2, crinecerfont dosing was at 22:00 on day 14; predose sampling was at 21:45. For cohorts 3 and 4, crinecerfont dosing was at 19:00 on day 14; predose sampling was at 18:45. 17OHP, 17-hydroxyprogesterone; ACTH, adrenocorticotropin; GC, glucocorticoid.
Figure 2. Twenty-four–hour profiles. For cohorts 1 and 2, crinecerfont dosing was at 22:00 on day 14; predose sampling was at 21:45. For cohorts 3 and 4, crinecerfont dosing was at 19:00 on day 14; predose sampling was at 18:45. 17OHP, 17-hydroxyprogesterone; ACTH, adrenocorticotropin; GC, glucocorticoid.CC BY-NC-ND · PubMed Central
Figure 3. Median percent reductions from baseline to day 14 based on morning window values. Based on each participant’s values from the morning window time points (06:00, 08:00, 10:00). The interquartile ranges (absolute value of Q3-Q1) for median percent reductions are shown in brackets. 17OHP, 17-hydroxyprogesterone; ACTH, adrenocorticotropin.
Figure 3. Median percent reductions from baseline to day 14 based on morning window values. Based on each participant’s values from the morning window time points (06:00, 08:00, 10:00). The interquartile ranges (absolute value of Q3-Q1) for median percent reductions are shown in brackets. 17OHP, 17-hydroxyprogesterone; ACTH, adrenocorticotropin.CC BY-NC-ND · PubMed Central
Figure 4. Percent change from baseline to day 14 in participants with crinecerfont 100 mg twice a day (cohort 4). Based on each participant’s average values from the morning window time points (06:00, 08:00, 10:00) on day 14 compared to the average of their morning window values at baseline. ACTH, adrenocorticotropin.
Figure 4. Percent change from baseline to day 14 in participants with crinecerfont 100 mg twice a day (cohort 4). Based on each participant’s average values from the morning window time points (06:00, 08:00, 10:00) on day 14 compared to the average of their morning window values at baseline. ACTH, adrenocorticotropin.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 56

Metadata

Authors
Auchus, R. J., Sarafoglou, K., Fechner, P. Y., Vogiatzi, M. G., Imel, E. A., Davis, S. M., Giri, N., Sturgeon, J., Roberts, E., Chan, J. L., & Farber, R. H.
Affiliations
  • University of Michigan (US)
  • University of Minnesota (US)
  • Seattle Children's Hospital (US)
  • Children's Hospital of Philadelphia (US)
  • Indiana University Indianapolis (US)
  • University of Colorado Anschutz (US)
  • Neurocrine Biosciences (United States) (US)
Corresponding author
Auchus, Richard J
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2021-10-15
Volume
107
Issue
3
Pages
801-812
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3206029402
Cited by
55
References
29
Citations by year
2026: 10 · 2025: 14 · 2024: 12 · 2023: 9 · 2022: 8 · 2021: 2
FWCI
2.43
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
Funders
Neurocrine Biosciences, Inc.
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
21-hydroxylase deficiency, classic congenital adrenal hyperplasia, CRF1 receptor antagonist, ACTH, 17-hydroxyprogesterone, androstenedione, testosterone, hyperandrogenism, cortisol production, dose comparison, safety and tolerability
MeSH terms
CRF Receptor, Type 1, Administration, Oral, Adolescent, Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Adult, Amines, Androstenedione, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Oxadiazoles, Testosterone, Thiazoles, Biomarkers, Treatment Outcome, Receptors, Corticotropin-Releasing Hormone, 17-alpha-Hydroxyprogesterone, Azabicyclo Compounds, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. https://app.cochat.ai/papers/10.1210/clinem/dgab749
The paper
Auchus, R. J., Sarafoglou, K., Fechner, P. Y., Vogiatzi, M. G., Imel, E. A., Davis, S. M., Giri, N., Sturgeon, J., Roberts, E., Chan, J. L., & Farber, R. H. (2022). Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgab749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.